Healthcare / Medical DevicesNasdaqGS
$6.09
-0.40 (-6.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-21.6M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$165M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-11.8%
↓Gross Margin
44.2%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
+21.2%
FCF CAGR
—
FCF margin
-6.2%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $348.7M · net income $-22.7M · FCF $-21.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | $348.7M | $348.7M | $335.7M | $315.7M | $377.2M | $311.7M | $280.2M | $340.5M | $336.0M | $225.5M | $168.2M | $113.6M | $73.1M | $44.9M | $28.7M |
| Net Income | $-22.7M | $-22.7M | $-35.9M | $-102.4M | $-83.8M | $-6.3M | $-5.8M | $20.9M | $51.8M | $21.0M | $20.5M | $11.6M | $6.8M | $25.4M | $564000.00 |
| EBITDA | $-9.5M | $-9.5M | $-21.5M | $-58.3M | $-9.6M | $30.9M | $6.6M | $33.6M | $49.2M | $39.9M | $36.4M | $29.1M | $22.6M | $13.0M | $5.8M |
| EPS | -0.86 | -0.86 | -1.52 | -4.42 | -3.67 | -0.28 | -0.27 | 0.94 | 2.30 | 0.96 | 0.97 | 0.56 | 0.30 | 0.68 | -19.97 |
| Gross Margin | 44.2% | 44.2% | 46.1% | 40.1% | 40.7% | 56.6% | 49.3% | 50.5% | 53.1% | 53.8% | 57.9% | 67.1% | 76.0% | 86.8% | 83.4% |
| Operating Margin | -8.7% | -8.7% | -12.7% | -24.2% | -8.8% | 3.0% | -4.3% | 5.8% | 11.3% | 12.2% | 13.6% | 13.2% | 14.4% | 9.9% | 2.9% |
| Net Margin | -6.5% | -6.5% | -10.7% | -32.5% | -22.2% | -2.0% | -2.1% | 6.2% | 15.4% | 9.3% | 12.2% | 10.2% | 9.3% | 56.6% | 2.0% |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.11 | 0.11 | 0.08 | — | — | — | — | — | — | 0.00 | 0.00 | -0.09 | — |
| Current Ratio | 3.10 | 3.10 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-21.6M | $-21.6M | $-11.2M | $-30.2M | $-58.8M | $18.2M | $32.6M | $37.5M | $51.9M | $57.6M | $29.3M | — | — | — | — |
| Returns | |||||||||||||||
| ROE | -11.8% | -11.8% | -20.6% | -50.0% | -28.2% | -1.7% | -1.7% | 6.1% | 16.7% | 9.3% | 11.3% | 8.6% | 5.8% | -40.8% | -0.7% |
| Valuation | |||||||||||||||
| P/B | 0.84 | 0.84 | 1.31 | 0.69 | 1.67 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| Revenue Growth | 3.9% | 3.9% | 6.4% | -16.3% | — | 11.3% | -17.7% | 1.3% | 49.0% | 34.1% | 48.0% | 55.4% | 62.8% | 56.4% | — |
| EPS Growth | 43.4% | 43.4% | 65.6% | -20.4% | — | -3.7% | -128.7% | -59.1% | 139.6% | -1.0% | 73.2% | 86.7% | -55.9% | 103.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.52 → -0.86
Residual
-5.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.